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Abstract:  
The epicardium and its derivatives provide trophic and structural support for the 
developing and adult heart. Here we tested the ability of human embryonic stem cell 
(hESC)-derived epicardium to augment the structure and function of engineered 
heart tissue (EHT) in vitro and to improve efficacy of hESC-cardiomyocyte grafts in 
infarcted athymic rat hearts. Epicardial cells markedly enhanced the contractility, 
myofibril structure and calcium handling of human EHTs, while reducing passive 
stiffness compared to mesenchymal stromal cells. Transplanted epicardial cells 
formed persistent fibroblast grafts in infarcted hearts. Co-transplantation of hESC-
derived epicardial cells and cardiomyocytes doubled graft cardiomyocyte proliferation 
rates in vivo, resulting in 2.6-fold greater cardiac graft size and simultaneously 
augmenting graft and host vascularization. Notably, co-transplantation improved 
systolic function compared with hearts receiving either cardiomyocytes alone, 
epicardial cells alone or vehicle. The ability of epicardial cells to enhance cardiac 
graft size and function make them a promising adjuvant therapeutic for cardiac repair.   
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Introduction: 
Despite major advances in the treatment of heart failure due to systolic impairment, 
therapeutic approaches have fallen short of addressing the cause of the problem; 
injury of the mammalian heart leads to irreversible loss of contractile myocardial 
tissue which is incapable of regeneration. At the turn of the millennium heart failure 
was widely identified as an emerging epidemic1. To date 5.6 million patients in the 
US alone and 23 million worldwide are suffering from heart failure with 50% dying 
within 5 years after being diagnosed2, 3. Current treatment is limited to ameliorating 
symptoms and slowing the natural progression of the disease but fails to compensate 
for the loss of contractile myocardium post-injury.  
Regenerative medicine may hold the key to effectively treating heart failure by using 
stem cell-derived cardiovascular cells and tissues to restore full contractile function4, 
5. Of all stem cell types, human pluripotent stem cells such as embryonic stem cells 
(hESC) and induced pluripotent stem cells (hiPSC) have the greatest potential for 
forming cardiovascular tissues, reliably giving rise to cardiomyocytes6-8, endothelial 
cells9, 10, smooth muscle cells11 and more recently also epicardial and endocardial-
like cells12-15 under chemically defined conditions. Furthermore, hESC-derived 
cardiomyocytes have been successfully used to remuscularize infarcted rat 8 and 
guinea pig16, 17 hearts, resulting in electrical integration and preserving cardiac 
function. The clinical potential of this technology has also been demonstrated in non-
human primate models, where transplantation of human or monkey pluripotent stem 
cell (PSC)-derived cardiomyocytes resulted in substantial remuscularization of the 
infarcted heart and restoration of cardiac function18-20.       
While mammalian heart regeneration has made progress, hurdles remain, such as 
relative immaturity of transplanted cells, suboptimal graft retention, insufficient 
cellular proliferation and a small graft size. In vitro, hPSC-derived cardiomyocytes 
derived from most protocols at best resemble cardiomyocytes found in a first 
trimester fetus, which may limit the functional benefits post-transplantation21. To date, 
little attention has been devoted to a supportive cell type that would promote maturity 
of hESC-derived cardiomyocytes and increase the graft size post-transplantation in 
vivo.   
4 
 
In early mammalian heart development, the epicardium plays a pivotal role as a 
progenitor cell source and provides trophic support for developing cardiomyocytes. 
Because the epicardium gives rise to cardiac fibroblasts and coronary smooth muscle 
cells, it is essential for the formation of a functioning connective tissue and coronary 
vasculature22, 23. Moreover, epicardium-derived cells are essential for cardiac 
proliferation and compaction24-26 and have been reported to promote cardiomyocyte 
maturation27-29. Given its trophic role in heart development we hypothesized that 
epicardial cells could promote cardiomyocyte maturation and contractility in hESC-
based 3D-engineered heart tissues (EHTs) in vitro and enhance engraftment and 
maturity leading to potential functional benefits when co-transplanted with hESC-
derived cardiomyocytes in vivo.    
We report here that hESC-derived epicardium promotes the development of 3D-
EHTs in vitro and cardiac grafts in vivo via cardiomyocyte maturation, proliferation 
and contraction. In the infarcted heart, hESC-derived epicardial cells (hESC-EPI) also 
increase endogenous neo-vessel development and enhance hESC-CM proliferation 
and subsequent maturation, thus creating larger grafts of human myocardium that 
further enhance ventricular function. By recapitulating key developmental steps, the 
epicardium augmented cardiomyocyte function, making it a promising adjuvant 
therapy in regenerative medicine.  
   
Results: 
HESC-derived epicardial cells promote cardiomyocyte maturation in 3D-EHT 
We first generated hESC-derived GFP-transgenic epicardial cells and wild-type (WT) 
cardiomyocytes as previously described8, 12, (Fig. 1a-b). Epicardial cells expressed 
epicardial and epithelial markers, WT1 and pan-cytokeratin, but no mesenchymal 
markers such as vimentin after their derivation in vitro12, 30. The functionality of 
epicardial cells was initially demonstrated through differentiating them to cardiac 
fibroblasts in vitro under chemically defined conditions that included VEGF and FGF. 
At the end of this differentiation protocol they expressed the fibroblast and 
mesenchymal markers, S100A4, DDR2 and vimentin, but lost their epithelial 
character indicating successful epithelial to mesenchymal transition (EMT). During 
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epicardial to fibroblast differentiation, WT1 was downregulated while the fibroblast 
marker S100A4 was gradually upregulated. (Supplementary Fig. 1a-e). 
Next, we tested the utility of epicardial cells in the context of 3D engineered heart 
tissues (EHTs). We incorporated epicardial cells along with hESC-CMs into collagen-
based 3D-EHTs31, which developed for 14 days under passive stress before they 
were subjected to histological and functional assessment (Fig. 1c-d). To investigate 
the potency of epicardial cells in 3D-EHT we compared them with constructs 
containing: (1) cardiomyocytes alone; (2) cardiomyocytes and hESC-derived 
mesenchymal cells; (3) cardiomyocytes and primary human mesenchymal stromal 
cells (MSCs) from bone marrow. Both epicardial cells as well as primary 
mesenchymal cells had the strongest effects on tissue remodelling and compaction 
whereas tissues containing high-purity cardiomyocytes alone demonstrated minimal 
compaction (Fig. 1e-g).  
Whilst in the tissues, hESC-EPI underwent EMT as indicated by the increase in 
expression of vimentin and decrease in pan-cytokeratin comparing constructs after 7 
days and 14 days of their development. In this context, epicardial derivates have 
previously been termed epicardium-derived cells (EPDCs)23. EPDCs are positive for 
Vimentin and S100A4, indicative of a fibroblast phenotype (Supplementary Fig. 2a-c).  
To determine the state of cardiomyocyte maturity, histological sections of the 3D-
EHTs were stained for sarcomeric proteins, and the sarcomere length, cell diameter, 
cell sectional area and myofibril alignment were quantified. HESC-EPI promoted the 
greatest sarcomere length, cell diameter, cell sectional area and myofibril alignment, 
which correlate with cardiomyocyte maturation, compared to primary MSCs, hESC-
derived MSCs or CM alone (Fig. 1h-j, supplementary Fig. 3a). 3D-EHTs containing 
hESC-EPI and primary MSC exhibited the greatest degree of sarcomeric 
organisation (Supplementary Fig. 3b). Furthermore, constructs containing hESC-EPI 
expressed more connexin 43, a marker of electrical connectivity between 
cardiomyocytes, compared to the other groups (Supplementary Fig. 2d-e). Gene 
expression by qRT-PCR demonstrated trends consistent with increases in the ratios 
of adult/fetal isoforms of contractile proteins (MYH7/MYH6, MYL2/MYL7 and 
TNNI3/TNNI1), all indicators of cardiomyocyte maturity (Supplementary Fig. 4). In 
conclusion, hESC-derived epicardial cells replicate key steps of early embryonic 
heart development in 3D-EHTs resulting in increased cardiomyocyte maturation.  
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HESC-derived epicardial cells enhance functional maturation of 3D-EHT 
We next tested whether the beneficial effects of hESC-derived epicardial cells 
observed histologically also translated to an increase in contractility. EHT constructs 
were transferred to a myograph with a length controller and a force transducer 
(Supplementary Fig. 5a); constructs containing CM and either hESC-MSC or primary 
MSC or hESC-EPI exhibited a Frank-Starling relationship, where twitch force 
increased linearly with increasing preload. In line with the histological finding that 
high-purity CM alone do not result in efficient tissue remodelling, cardiomyocyte 
maturation or electrical connectivity, we did not observe coordinated contraction or 
measurable force production in 3D-EHTs containing CM alone. Constructs containing 
hESC-EPI produced the greatest total force amongst the 4 groups.  Additionally, 
EHTs containing hESC-EPI showed the greatest increase in active force production 
with increasing strain (i.e. the greatest contractility) compared to primary MSCs and 
hESC-MSCs (Fig. 2a, Supplementary Fig. 5b). At the same time, 3D-EHTs 
containing hESC-EPI produced the least passive force compared to primary MSCs or 
hESC-MSCs, which would correspond to a more compliant tissue with better 
relaxation potential during diastole (Fig. 2b).  
When assessing the Ca2+-handling of the constructs, those containing hESC-EPI and 
primary MSCs accounted for the most mature Ca2+ transients (Fig. 2c-d). Constructs 
containing EPDCs had more rapid Ca2+-release and Ca2+-decay compared to those 
with primary MSCs (Fig. 2e, Supplementary Fig. 5c-d). Constructs containing hESC-
MSC displayed irregular and broad Ca2+ transients, reflecting less coordinated 
beating. In those containing CM-only, no coordinated Ca2+ transients were 
detectable, but rather asynchronous contraction of single non-connected 
cardiomyocytes was observed, which translated to noise in multicellular regions of 
interest.  
Next, we tested if the ability of epicardial cells to promote 3D-EHT function is 
independent of the parental hESC line.  We generated EHTs where cardiomyocytes 
and EPDCs were differentiated from the same H9 line, as well as with 
cardiomyocytes from H9 cells and EPDCs from RUES2 hESCs.  In both contexts, the 
EPDC-containing EHTs showed superior contractility and Ca2+ dynamics compared 
to EHTs made with hESC-MSCs or primary MSCs. These experiments demonstrated 
that enhancement of EHT function by EPDCs is a general attribute of epicardial cells 
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and not a line-dependent artefact (Supplementary Fig. 6a-b, Supplementary Fig. 7a-
d).  
Furthermore, in a separate experiment we determined the nature of the non-
cardiomyocyte population obtained upon differentiation of high-purity cardiomyocytes 
by flow cytometry using markers previously described32. We found positivity for THY1 
and PDGFR-β and to a minor degree for CD31 and NKX2.5 in this cTnT-negative cell 
population (Supplementary Fig. 8). Overall, this demonstrated a mesenchymal and 
fibroblast-like nature to these non-cardiomyocytes and was comparable between 
RUES2- and H9-derived cells.     
In conclusion, hESC-derived epicardial cells promote functional maturation of 3D-
EHT. These findings encouraged us to explore their use in vivo as an adjunct to 
cardiomyocyte transplantation for cardiac repair. 
Epicardial cells engraft and differentiate in the myocardial infarct 
To assess the response of hESC-derived epicardial cells to engraftment in vivo we 
performed a series of pilot transplants into the infarct zone of athymic rats 
(Supplementary Fig. 9a). Because most non-myocytes that are transplanted into the 
heart rapidly die33, we subjected the epicardial cells to heat shock and a prosurvival 
cocktail (PSC) of anti-apoptotic and anti-necrotic factors. At 7 days post-
transplantation we found small grafts in 3 out of 4 animals receiving 2x106 cells and 
larger grafts in all 4 animals receiving 4x106 cells (Supplementary Fig. 9b-c). To 
maximise survival at 28 days post-transplantation, we delivered 6x106 cells and 
found large grafts in 6 out of 6 animals (Supplementary Fig. 9d), indicating the grafts 
survive long term. We confirmed in a separate experiment that delivery with heat 
shock + PSC is required for engraftment of epicardial cells (Supplementary Fig. 10a-
c). Conversely, epicardial cell transplantation in NOD scid gamma mice, without heat 
shock + PSC, demonstrated no detectable graft formation at 28 days (Supplementary 
Fig. 11a-c).  
At 7 days post-transplantation the EPDCs co-expressed pan-cytokeratin and 
vimentin, indicating ongoing EMT.  At 28 days post transplantation EMT was 
essentially complete, with all grafted cells expressing vimentin and almost no 
detectable expression of pan-cytokeratin (Supplementary Fig. 9e-f). A small 
subpopulation of grafted vimentin-positive cells co-expressed WT1 on day 7 and day 
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28. This reflects the human fetal heart, where activated vimentin+ epicardial cells 
invade the compact myocardium with a subpopulation retaining WT1 expression 
(Supplementary Fig. 9g-g’). At 28 days the grafted epicardial cells expressed 
S100A4, suggesting a fibroblast phenotype, whereas they neither expressed SM22α 
nor integrated into blood vessel walls, (Supplementary Fig. 12a-b). Grafted cells were 
negative for the cardiac marker α-actinin and the endothelial marker human Lectin 
(Supplementary Fig. 12c-e). Taken together, these data indicate that EPDCs 
differentiate into cardiac fibroblast-like cells with no formation of cardiomyocytes, 
endothelial cells or smooth muscle cells. 
Because EPDCs readily form smooth muscle cells in vitro, we hypothesized that the 
infarct environment inhibited this differentiation pathway. To test this, we delivered 
hESC-EPI in PSC onto the chorionic vasculature of chick embryos.  After 5 days the 
human EPDCs had integrated into the walls of host vessels and expressed SM22 
(Supplementary Fig. 13a-c). Thus, the epicardial cells are multipotent and in an 
embryonic environment readily differentiate into vascular smooth muscle, whereas in 
the adult infarct they form fibroblast-like cells.   
Co-transplantation of epicardial cells and cardiomyocytes augments 
microvascular density  
The long-term persistence of hESC-derived epicardial cells in infarcted hearts led us 
to hypothesize that these cells would exhibit a trophic effect on grafted hESC-
cardiomyocytes and the host myocardium. To test this, we performed a co-
transplantation study where four groups of athymic rats either received an injection of 
5x106 hESC-derived epicardial cells (EPI), 10x106 hESC-derived cardiomyocytes 
(CM), the combination of both (EPI+CM: 5x106 hESC-derived epicardial cells plus 
10x106 cardiomyocytes) or vehicle control (PSC; Fig. 3a). Four weeks post 
transplantation no difference in infarct size was found between the groups, ruling out 
effects on infarct scar healing (Fig. 3b-c).  
To assess whether cell transplantation had an effect on host vessel recruitment, we 
quantified the microvascular density in the cardiac grafts, the infarct zone and the 
non-injured border zone (Fig. 3d). Microvascular density was significantly increased 
in cardiac grafts of animals that were co-transplanted with epicardial cells and 
cardiomyocytes. Furthermore, erythrocytes were readily detectable in the lumens of 
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the vessels, indicating perfusion via the coronary circulation (Fig. 3e, Supplementary 
Fig. 14a). We also observed an increase in microvascular recruitment in the infarct 
zone and in the non-injured border zone of the infarct, which was highest in EPI+CM, 
followed by CM, then EPI and finally vehicle control (Fig. 3f-g). To assess the timing 
of microvascular sprouting we made use of our pilot trial dataset and demonstrated 
that, epicardial cells alone lead to a significant increase in microvascular density in 
the infarct- and borderzone by day 28 but not by day 7 post transplantation, 
indicating delayed angiogenic effects (Supplementary Fig. 14b-e).   
To address the maturity of neo-vessels we also screened the three areas of interest 
for presence of smooth muscle cell coated arteries. Vessels containing SM22α+ 
mural cells were abundant in the infarct zone and the border zone of all groups. 
However, when assessing their presence within cardiac grafts we observed smooth 
muscle cell coated vessels in the EPI+CM group but not in the CM-alone group, 
suggesting epicardial cells promote smooth muscle encoatment and vascular 
maturation within the graft (Supplementary Fig. 14f-k). Absence of co-staining for 
SM22and human mitochondria further confirmed that the smooth muscle coats 
were rat-derived, and that epicardial cells were also not able to differentiate to 
smooth muscle cells in the infarct zone in the presence of cardiomyocytes 
(Supplementary Fig. 14l). In summary, hESC-derived epicardial cells create a more 
highly vascularized cardiac graft, and microvascular density surrounding scar and 
border zone, which should promote a more favourable niche for hESC-cardiomyocyte 
engraftment and function.                
Co-transplantation promotes cardiac graft size, proliferation and maturity 
We next assessed the effects of epicardial cells on the cardiac grafts. Given the 
trophic effects of epicardial cells on cardiomyocytes in vitro we first investigated 
whether co-transplantation would affect cardiac graft size. Cardiac grafts were readily 
identified with antibodies directed against -MHC (MYH7; whereas rat 
cardiomyocytes predominantly express α-MHC/MHY6) and co-expressed α-actinin. 
Cardiac grafts were 2.6-fold larger when cardiomyocytes were co-transplanted with 
epicardial cells, compared to cardiomyocytes alone, averaging 3.9±1.6% of the left 
ventricle vs 1.5±0.9% of the left ventricle, respectively (Fig. 4a-b; Supplementary Fig. 
14m).  
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Because epicardial cells secrete growth factors for cardiomyocytes during 
development, we hypothesized that epicardial cells augmented graft size via 
increased cardiomyocyte proliferation.  All rats in this phase of the study were pulsed 
with the thymidine analogue, BrdU, on 1, 3, 7 and 14 days post-cell delivery. To 
determine cumulative proliferation rates in the grafts we stained with antibodies 
directed against BrdU and the human-specific cardiac marker β-MHC. The 
proliferative index of β-MHC positive cells was 2-fold higher in animals that received 
the combination of hESC-EPI and cardiomyocytes (8%±1.4%) compared with 
cardiomyocytes alone (4±0.9%, p<0.0001; Fig. 4c-d). Conversely, there was no 
difference in the proliferative index of vimentin-positive EPDCs in animals receiving 
epicardial cells alone or epicardial cells with cardiomyocytes (Supplementary 
Fig.15a-b). Taking the graft cardiomyocyte BrdU rates as daily averages of DNA 
synthesis, and assuming that the cell cycle lasts 24 hours, hESC-CM graft expansion 
can be calculated for each group. For 28-day grafts, control expansion would be 
1.04^28, or 3.0-fold expansion, while in co-transplantation studies it would be 
1.08^28, or 8.6-fold expansion. This predicts a 2.9-fold difference in graft size, which 
is quite close to our observed 2.6-fold difference.  Thus, although we cannot rule out 
a role for increased graft survival, these data indicate that enhanced cardiomyocyte 
proliferation is a major driver for the increased cardiomyocyte graft size observed 
with hESC-derived epicardial cell co-transplantation. 
Given the epicardial effects on cardiomyocyte maturation in vitro, we assessed the 
sarcomere length of the cardiac grafts. In line with our findings in vitro, 
cardiomyocytes that were co-transplanted with epicardial cells exhibited a greater 
sarcomeric length and cell diameter as well as a 77% larger cell sectional area (Fig. 
4f-h) than those that were transplanted alone, indicative of a more mature phenotype. 
Additionally, we demonstrated that co-transplantation of cardiomyocytes with 
epicardial cells leads to an isoform switch from ssTnI to cTnI in cardiac grafts (Fig. 
4e).  
As cardiac fibrosis impedes structural integration of grafts and host34, we were 
concerned that epicardial cell-derived fibroblasts might interfere with gap junctions 
between graft and host cardiomyocytes. To investigate this, we performed combined 
immunostaining for β-MHC, cTnT and the gap junction protein connexin43. Gap 
junctions between graft and host were seen in multiple areas across all animals, 
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demonstrated by connexin43 expression between neighbouring human and rat 
cardiomyocytes (Fig. 4i). While, epicardial cells themselves can express 
connexin4335, 36, the gap junctions identified in our study were predominantly 
between cardiomyocytes. In conclusion, hESC-derived epicardial cells promote 
cardiac graft size, in part through proliferation, and they enhance maturation/myofibril 
development, while still permitting structural integration of grafted cardiomyocytes 
with the recipient myocardium.  
Co-transplantation promotes cardiac function  
To assess the functional effects of cardiac grafts on global host heart function, we 
performed cardiac ultrasound on all animals prior to infarction, immediately before 
cell injection and after 28 days of follow-up. The ultrasound scans (AM) and their 
interpretations (JB and FW) were performed by investigators who were blinded to the 
treatment to prevent bias.  All groups exhibited comparable left ventricular (LV) 
dilation and decline in LV function after infarction, consistent with the histological 
finding of comparable infarct sizes (Fig. 5a-c; supplementary table 1).  Compared 
with their pre-injection (post-infarction) baseline values, the vehicle control group 
displayed a 9±5.4% decline in fractional shortening by 4 weeks after injection, 
indicating a progression towards heart failure (p<0.0001 vs. baseline). The EPI group 
showed a 5.3±6.5% decline in fractional shortening.  Similar to previous reports from 
our group8, transplantation of cardiomyocytes-only preserved cardiac function over 
the 4-week period, indicating that CM transplantation prevented the progression to 
heart failure.  Importantly, animals receiving combined CM+EPI grafts showed a 
4.5±3.6% improvement in fractional shortening, indicating that co-transplantation 
significantly improved LV function (p=0.0175 vs. cardiomyocytes-only). Furthermore, 
we demonstrated that in the CM and CM+EPI groups, improvements in LV function 
correlate linearly with graft size (Supplementary Fig. 15c).     
Comparing pre- and post-injection values, left-ventricular end-systolic dimension 
(LVESD) remained stable in the CM+EPI group and increased in the CM only group, 
followed by greater increases in the EPI and the vehicle control group. The change in 
LVESD in the CM+EPI group was significantly smaller than in the vehicle control 
group but the difference to the CM only group or the EPI group did not reach 
statistical significance (Fig. 5d-e). For left ventricular end diastolic dimension 
(LVEDD), ANOVA did not yield a significant difference (Fig. 5f-g). Taken together, 
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these studies show that co-transplantation of hESC-derived epicardial cells with 
cardiomyocytes leads to a greater increase in cardiac function compared to 
transplantation of cardiomyocytes alone. Furthermore, this benefit manifests 
principally as enhanced systolic function rather than impacting left ventricular 
remodelling. 
To investigate whether these effects would be present in the long term, we followed a 
subset of 4-5 animals per group for up for 3 months. Three months after cell grafting 
hESC-EPI as well as hESC-derived cardiomyocytes were still present in the infarct 
zone as confirmed by anti-human mitochondrial staining (Supplementary Fig. 16a-c). 
In line with the 28-day follow-up, at 84 days post transplantation no differences were 
found in infarct size between the four study groups (Supplementary Fig. 16d). 
Functional analysis demonstrated long-term perpetuation of benefits perceived at 1 
month due to persistent systolic improvement. Fractional shortening showed no 
decline in animals receiving CM+EPI or CM-only but a significant decline in animals 
receiving either EPI or vehicle control. While there was no difference in the change of 
fractional shortening between day 28 and day 84 among the groups, the change 
occurring between day 4 and day 84 was significantly greater in the CM+EPI group 
compared to CM only or EPI only or vehicle control (Supplementary Fig. 16e-f). 
Indeed the 4.5% improvement in FS of epicardial cell co-therapy over 
cardiomyocytes alone seen at 4 weeks increased further to 9.6% by 12 weeks 
(Supplementary Fig. 16f). To summarise, hESC-derived cellular grafts and related 
functional improvement in cardiac function persist in the long term.   
RNA-sequencing reveals the epicardial secretome 
Finally, to address the question of putative mediators of epicardial cell-driven cardiac 
repair we performed RNA sequencing of hESC-derived epicardium as used for all in 
vitro and in vivo experiments. In embryonic heart development, the neural crest (NC) 
is essential for pharyngeal arch organisation and outflow tract septation but lineage 
tracing studies have to date not suggested a role in cardiac maturation37-39. We first 
used hESC-derived NC cells in 3D-EHTs, demonstrating the inability of this cell 
population to result in structural and functional heart maturation, in contrast to 
epicardial cells (Supplementary Fig. 17a-b). We therefore used NC cells as a 
negative control for RNA-sequencing (Fig. 6a, Supplementary table 2).  
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As epicardial cells resulted in stark effects on tissue remodelling of 3D-EHTs and 
because it has been demonstrated that the extracellular matrix plays a key role in 
epicardial-driven heart repair, we focused on extracellular matrix molecules secreted 
by epicardial cells and differentially expressed in the hESC-derived NC cells 
(Supplementary table 2). The heatmap shown in Figure 6a displays differentially 
expressed genes with an adjusted p-value <1x10-7 (a complete list of the genes and 
their expression is shown in supplementary table 2). Amongst them, Fibronectin is 
one of the most differentially expressed candidates. We then performed a gene 
ontology (GO) enrichment analysis, which further highlights a potential role for ECM 
expressed by hESC-EPI in myocardial development and maturation (Fig. 6b-c, 
Supplementary Fig. 18).   
We first demonstrated that Fibronectin was also abundantly expressed at the protein 
level in 3D-EHT containing epicardial cells but to a lesser degree in constructs 
containing hESC-MSC, primary MSC or cardiomyocytes alone (Fig. 6d). 
Furthermore, Fibronectin was highly expressed in cardiac grafts in vivo in animals 
receiving epicardial cells and cardiomyocytes or epicardial cells alone but only at a 
rudimentary level in those receiving cardiomyocytes alone or vehicle control (Fig. 6e). 
In summary, RNA-sequencing has provided the secretome of hESC-derived 
epicardium and identified a potential involvement of extracellular matrix remodelling 
in the process of cardiac maturation in vitro and in vivo. These data provide a 
valuable target library for future cardiac repair strategies.  
Discussion: 
This study was designed to address two gaps in knowledge: the immaturity of hPSC-
derived cardiomyocytes, and the inefficient remuscularization of infarcts following 
hPSC-CM transplantation. Because of the key trophic role played by the epicardium 
during development, we hypothesized that hPSC-epicardial cells would promote 
cardiomyocyte proliferation and maturation, resulting in better EHT formation in vitro 
and better infarct remuscularization in vivo.  We found that hESC-derived epicardial 
cells undergo EMT to fibroblast-like cells both in vitro and in vivo. In EHTs EPDCs 
augment tissue structure and function, resulting in increased cardiomyocyte size, 
sarcomere length, force production and augmented Ca2+ handling.  When co-
delivered with hESC-CMs into myocardial infarcts, EPDCs stimulate hESC-CM 
proliferation, increasing remuscularization by 2.6-fold. Additionally, EPDCs stimulate 
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vascularization within the graft, infarct scar and in the borderzone host myocardium.  
These changes are accompanied by remodelling of the ECM, including high levels of 
fibronectin deposition. Finally, co-delivery of hESC-derived epicardium with hESC-
CM results in significantly improved ventricular function post-infarction. 
 
The pivotal role of the epicardium in heart development is well recognized. During 
early embryonic heart formation the epicardial tissue gives rise to coronary smooth 
muscle cells22, 23 and myocardial fibroblasts24, 25, 40. While smooth muscle cells are 
critical for formation of the coronary vasculature, cardiac fibroblasts are essential for 
myocardial proliferation and compaction26. Conversely, inhibiting proepicardial 
outgrowth results in pathologic formation of the coronary vessels and non-
compaction cardiomyopathy41. The trophic effect of quail and rat epicardium-derived 
cells has been demonstrated in co-culture experiments resulting in structural and 
functional maturation of cardiomyocytes27, 29. Our data show that co-culture of hESC-
derived epicardial cells and cardiomyocytes results in compaction and structural as 
well as functional maturation of 3D-EHT. More specifically we demonstrate that 
hESC-derived epicardium outcompetes both hESC-derived MSCs as well as primary 
MSCs in terms of force generation and Ca2+-handling, corroborating the functional 
role of its embryonic identity. The functional potency of epicardial cells might prove 
broadly applicable to current tissue engineering strategies, that would benefit from 
enhanced structural integrity and function of cardiomyocytes42.  
In neonatal mice and in zebrafish, the epicardium is thought to have a key role in 
facilitating myocardial regeneration following injury43, 44; in contrast the adult 
mammalian heart displays inadequate epicardial activation and fails to regenerate 
myocardium post-injury. In this context it has been demonstrated that embryonic 
cardiac fibroblasts induce greater cardiac proliferation than their adult counterparts26. 
Consequently, we propose that the fetal-stage epicardium generated by hESCs may 
preferentially promote regeneration. 
It is important to consider the mechanism of action through which the epicardial cells 
improve the impact of cardiomyocyte transplantation. Since cardiomyocytes are 
already effective by themselves, the 2.6-fold enhancement of cardiomyocyte 
engraftment induced by epicardial cell co-delivery may underlie much of the benefit 
on cardiac function. The positive correlation of cardiac graft size and delta FS (%) 
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corroborates this interpretation (Supplementary Fig.15c). Most of this increase in 
engraftment can be accounted for by the 2-fold increase in cardiomyocyte DNA 
synthesis rates induced by epicardial cell co-delivery, although beneficial effects on 
cardiomyocyte survival cannot be ruled out. Another important factor, however, is that 
the EPDCs induced a significant amount of angiogenesis in the graft, infarct scar and 
boderzone host myocardium. Increased vascularization should improve the function 
of both graft and host tissues and could contribute to the beneficial effect.   
A third potential mechanism was raised by our RNA-seq studies, which demonstrated 
that hESC-derived epicardial cells synthesize an embryonic ECM that is particularly 
rich in fibronectin. It has been demonstrated that the secretion of fibronectin by 
epicardial cells is required for heart regeneration in zebrafish45. In line with these 
findings it was demonstrated that the orchestrated secretion of fibronectin, collagen 
and heparin-binding EGF-like growth factor by embryonic but not adult fibroblasts 
resulted in cardiomyocyte proliferation26. We therefore propose that the matrix laid 
down by hESC-derived epicardial cells is likely to exhibit developmental cues that are 
absent in mature post-infarct myocardium, providing an advantageous niche in a 
hostile environment and the GO analyses of RNA sequencing data are in support of 
this. Further elucidation of the observed crosstalk between epicardium and 
cardiomyocytes might aid ongoing tissue engineering and cell therapy endeavours 
and the extensive data on epicardially-expressed genes made available here 
provides a rich resource for further study. These mechanisms are not mutually 
exclusive and could co-exist.   
Finally, although we favour the notion that the salutary effects of co-delivering 
cardiomyocytes plus epicardial cells results from the impact on cardiomyocyte graft 
size, vascularization and ECM, we cannot rule out a paracrine effect from simply 
increasing the number of delivered cells in the combined cell group. Indeed, our data 
do not permit distinguishing the direct mechanical effects of the cardiomyocyte grafts 
from the paracrine factors they secrete; presumably both mechanisms may co-exist 
and be augmented by larger cardiomyocyte grafts. However, this does not detract 
from our primary conclusion that hESC-derived epicardial cells recapitulate their 
embryonic role in the post-MI setting by promoting hESC-derived cardiomyocyte 
proliferation and maturity and at the same time favourably influencing host tissue 
regeneration. 
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Two other pioneering studies have demonstrated that human primary epicardial cells 
improve function of the infarcted heart and that co-transplantation of adult 
cardiovascular progenitors with epicardial cells exerts a synergistic effect that 
exceeds that of monotherapy33, 46. There were several important differences with our 
study, including their use of epicardial cells and cardiac progenitor cells derived from 
the adult human heart (vs. our use of hESC derivatives) and their use of NOD-SCID 
mice with permanent coronary ligations (vs. our use of athymic rats with ischemia-
reperfusion injury). While these results demonstrated a beneficial effect of poly-cell 
therapy, the authors did not detect stable grafts in any of the groups, indicating that 
the effects seen were paracrine in nature. Indeed, we are not aware of any studies in 
the literature that have demonstrated robust cardiomyocyte and supportive cell type 
engraftment in the long term following myocardial infarction. In contrast, our grafts, 
both cardiac as well as epicardial, and related functional benefits were detectable up 
to three months post transplantation, providing evidence for longevity and potential 
perpetuation of benefits in the long term.  
In conclusion, hESC-derived epicardial cells are a promising tool to advance 
regenerative cardiovascular medicine, including cell transplantation as well as tissue 
engineering strategies. Future studies are warranted to better understand the 
mechanisms through which epicardial cells propagate the observed benefits and 
investigate their function in models that more closely match clinical application. 
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Figure Legends: 
Figure 1. Generation and maturation of 3D-EHT using hESC-derived epicardial 
cells and cardiomyocytes.  
(a) Epicardial cells derived from hESCs expressing the epicardial markers BNC1 and 
WT1. Scale bar: 50μm. (b) Purity of epicardial cells and cardiomyocytes by flow 
cytometry. Control groups represent secondary and isotype antibodies for epicardial 
cells and cardiomyocytes respectively. Flow cytometric analysis was independently 
repeated 3 times with similar results. (c) Schematic of experimental design. 
Epicardial cells and cardiomyocytes were derived from hESCs and co-cultured in 3D-
EHT. (d) Schematic of 3D-EHT using hESC-derived epicardial cells and 
cardiomyocytes. (e-f) Compaction and ultrastructure of 3D-EHT containing CM alone, 
CM+hESC-MSC, CM+Primary MSC or CM+hESC-EPI. Scale bars: 2.5mm and 
25μm. (a, e-f) Experiments were independently repeated 9 times with similar results.  
(g-j) Quantification of tissue remodelling, sarcomeric length, cell diameter and cell 
sectional area.   
Mean values; error bars represent SD. Two-sided p-values were calculated using a 
one-way ANOVA with post-hoc correction for multiple comparisons. CM alone, 
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CM+hESC-MSC, CM+Primary MSC and CM+hESC-EPI, n=9, 9, 8, 9 constructs, 
generated independently and measured on three different days.  
 
Figure 2. HESC-derived epicardial cells promote contractility and Ca2+-handling 
of 3D-EHT. (a) Active force generation of 3D-EHT containing CM alone, CM+hESC-
MSC, CM+Primary MSC or CM+hESC-EPI. Displayed are the Frank-Starling curve of 
active force production and the slope of the generated curve, respectively. (b) 
Passive force of 3D-EHT containing CM alone, CM+hESC-MSC, CM+Primary MSC 
or CM+hESC-EPI. Displayed are the curve of passive force production and the slope 
of the generated curve respectively. (c) Representative Ca2+ traces of 3D-EHT. (d) 
Overlay of representative Ca2+ curves. (e) Slope of Ca2+-upstroke and Ca2+-
downstroke. Mean values; error bars represent SD. Dotted lines represent 95% 
confidence intervals. Two-sided p-values were calculated using a one-way ANOVA 
with post-hoc correction for multiple comparisons. CM alone, CM+hESC-MSC, 
CM+Primary MSC and CM+hESC-EPI, n=9, 9, 8, 9 constructs, generated 
independently and measured on three different days.   
  
Figure 3. Co-transplantation of hESC-derived epicardial cells with 
cardiomyocytes promotes microvascular density. (a) Schematic of study design. 
(b) Representative Picrosirius Red-Fast Green counterstained infarcted rat heart 
sections. (c) Quantification of myocardial infarct size. (d) Schematic of areas 
assessed for vascularisation. (e) Microvascular density in cardiac grafts. (f) 
Microvascular density in the infarct zone. (g) Microvascular density in the non-injured 
border zone of the infarct. Due to the presence of erythrocyte autofluorescence all 
quantification was performed manually to avoid erroneous detection with automated 
software.   
Mean values; error bars represent SD. Two-sided p-values were calculated using a 
one-way ANOVA with post-hoc correction for multiple comparisons unless otherwise 
stated. N=36 in total for histologic analysis at the 1-month time point. Control, EPI, 
CM, CM+EPI, n=9, 10, 8 and 9 animals. Scale bars: 50μm.     
 
Figure 4. HESC-derived epicardial cells potentiate cardiac regeneration. (a) 
Representative sections of infarcted hearts demonstrating the cardiac grafts in 
animals that received either hESC-derived epicardial cells and cardiomyocytes or 
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cardiomyocytes alone. βMHC is specific for grafted human cardiomyocytes while 
cTnT antibody stains both rat and human cardiomyocytes. Scale bar: 2.5mm. (b) 
Quantification of cardiac graft size. (c) Proliferative index of human cardiomyocytes in 
cardiac grafts. Scale bar: 20μm. (d) Quantification of proliferative index. (e) Isoform 
switch of SSTnI to cTnI in cardiomyocytes in vivo in animals receiving EPI+CM and 
CM alone. Staining performed in 5 animals per group. Scale bars: 20μm. (f) 
Quantification of sarcomeric length. (g) Quantification of cell diameter in 
cardiomyocytes in vivo. (h) Quantification of cell sectional area in cardiomyocytes in 
vivo. (i) Cardiac grafts and Cx43+ gap junctions with host tissue. Scale bars 50μm for 
(i) and 20μm for (*) and (**). (i) CX43 staining was performed on all animals. Mean 
values; error bars represent SD. Two-sided p-values were calculated using an 
unpaired t-test unless otherwise stated.  N=37 in total for histologic analysis after 1 
month; Control, EPI, CM, CM+EPI, n=9, 10, 9 and 9 animals.  
 
Figure 5. Co-transplantation of epicardial cells and cardiomyocytes promotes 
functional recovery.  
(a) Schematic of study design and timing of echocardiographic data collection. (b) 
Echocardiographic effects of hESC-derived epicardial cell augmented cardiac grafts 
on postinfarct ventricular function. Fractional shortening values are given for the 96hr 
pre-treatment baseline and 1-month follow-up. (c) Difference in fractional shortening. 
(d) Left-ventricular end-systolic dimension (LVESD) are given for the 96hr pre-
treatment baseline and 1-month follow-up. (e) Difference in LVEDS. (f) Left-
ventricular end-diastolic dimension (LVEDD) are given for the 96hr pre-treatment 
baseline and 1-month follow-up. (g) Difference in LVEDD.      
Mean values; error bars represent SD. Two-sided p-values were calculated using a 
paired t-test for comparison of cardiac function within groups between baseline and 
1-month follow-up. If more than 2 groups were compared, a one-way ANOVA with 
post-hoc correction for multiple comparisons was used. N=56 in total for functional 
analysis after 1 month; Control, EPI, CM, CM+EPI, n=13, 15, 14 and 14 animals.  
     
Figure 6. Epicardial secretome. (a) Heatmap depicting differentially expressed 
secreted factors in epicardial cells compared to neural crest. (b) Gene enrichment 
analysis showing the top enriched GO biological processes. The 705 genes 
specifically enriched in the EPI secretome were subjected to a hypergeometric test 
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against a background of the 2413 secretome genes expressed in NC or EPI. GO 
terms are shaded between black and white based on their false discovery rate after 
Benjamini–Hochberg correction. (c) Circular GO plot depicting the top GO terms 
enriched in EPI vs. NC associated with at least 10 genes on the right and the 
associated genes on the left. Genes are shaded between black and white based on 
their fold enrichment in EPI compared with NC. (a-c) EPI and NC, n=3 and 3. (d) 
Fibronectin expression in 3D-EHT in vitro. CM alone, CM+hESC-MSC, CM+Primary 
MSC and CM+hESC-EPI, n=9, 9, 8, 9 constructs, generated independently and 
measured on different days. Scale bars 50μm. (e) Fibronectin expression in 
epicardial and cardiac grafts in animals in vivo. Scale bars 50μm. This staining was 
performed on all animals at the 1-month time point (n=37).   
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